Publications by authors named "Chris Douglass"

Article Synopsis
  • - The ATTEST-2 trial evaluated if tenecteplase, a newer thrombolytic agent, is at least as effective as the standard alteplase within 4.5 hours of an acute ischaemic stroke by comparing outcomes like the modified Rankin Scale (mRS) at 90 days post-treatment.
  • - Conducted across 39 UK stroke centers, the study randomly assigned 1,777 eligible stroke patients to receive either tenecteplase or alteplase, focusing on their recovery outcomes and safety, including complications such as bleeding.
  • - Results showed that tenecteplase was non-inferior to alteplase regarding the distribution of mRS scores, but it did not
View Article and Find Full Text PDF

First described by Fischer in 1962, the limb shaking syndrome is a haemodynamic transient ischaemic attack (TIA) clinically characterised by brief, dysrhythmic, flailing or jerking movements, involving limbs contralateral to an occlusion of the internal carotid artery (ICA), which occur with a change in posture such as standing from sitting. We present the case of a woman in her 60s who presented with left-sided weakness suggestive of right hemispheric stroke, with previous episodes of limb shaking TIAs, which were caused by significant cerebral hypo-perfusion due to a combination of postural hypotension and a significant stenosis of the left ICA.

View Article and Find Full Text PDF

The COVID-19 pandemic is revealing growing reports of atypical presentation of the disease beyond the respiratory system. SARS-CoV-2 infection has been linked to multisystem vasculopathy including cardiopulmonary, cerebral and renal vasculature, potentially brought on by a dysregulated host immune response in a probable setting of a cytokine storm. Here, we describe a case of a previously healthy and active 74-year-old man presenting with acute cognitive decline with preceding non-specific influenza-like symptoms.

View Article and Find Full Text PDF

Background: Orolingual angio-oedema is a recognised complication of tissue plasminogen activator (tPA) for ischaemic stroke. We investigated its incidence, clinical characteristics and relationship with other factors in patients receiving tPA at a UK centre.

Methods: 530 consecutive patients (median age 70 years) receiving tPA treatment for confirmed ischaemic stroke were included.

View Article and Find Full Text PDF